|Articles|October 1, 2021

Delta Variant Causes Unprecedented COVID-19 Disease in Children

Author(s)Nina Cosdon

The Arkansas Health Department’s research showed that, as with the rest of the population, Delta is severely infectious for children.

COVID-19 is commonly believed to cause mild to asymptomatic cases when contracted by children (18 years of age and younger). However, the emergence of the more infectious Delta variant (B.1.617.2) as the dominant strain in Arkansas led the Arkansas Department of Health (ADH) to investigate whether this is still the case.

Delta did not become the leading variant in Arkansas until the first week in July 2021, but children were contracting COVID-19 at schools during the January 2021 surge even with physical mitigation measures (PMM).

ADH’s findings, presented at the virtual IDWeek conference, showed that there were 31.6% fewer pediatric COVID-19 cases in July 2021 than in January 2021 (8031 versus 11735), but pediatric hospitalization, ICU admission, mechanical ventilation, and death all peaked in July 2021.

Among children infected with the Delta variant, hospitalization was up by 41.9% (n=105), ICU admissions increased 68.6% (n=18), and ventilator use raised by 300% (n=8).

The one pediatric death recorded was the first in Arkansas since the start of the COVID-19 pandemic.

The results disproved any misconceptions about pediatric COVID-19 cases lacking severity.The ADH predicted that the July 2021 Delta outbreak would only result in more pediatric cases as schools opened in the fall, leading them to recommend schools update and reinstate their PMM efforts.


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.